MS
REGN icon

Madden Securities’s Regeneron Pharmaceuticals REGN Stock Holding History

Madden Securities’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-36
Closed -$26K – 296
2022
Q4 		$26K Buy
+36
New +$26.6K 0.01% 250

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Madden Securities's REGN Position: Q1 2023 in Review

Madden Securities sold out of Regeneron Pharmaceuticals (REGN) in Q1 2023, closing a stake of 36 shares — an estimated $26K sold.

Madden Securities first reported a position in REGN in Q4 2022 and held it in 1 quarter. The position peaked at $26K in Q4 2022. 1,192 funds tracked by Wall St. Rank hold REGN as of Q1 2023.

  • Madden Securities reported no remaining Regeneron Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Madden Securities sold 36 Regeneron Pharmaceuticals shares in Q1 2023, an estimated $26K.
  • Madden Securities first reported a position in Regeneron Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • Madden Securities's Regeneron Pharmaceuticals position peaked at $26K in Q4 2022.
  • 1,192 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2023.

Based on Madden Securities's 13F filing for Q1 2023, filed 21 Apr 2023.